Heart failure highlights in 2012-2013

Licette C. Y. Liu; Kevin Damman; Eric Lipsic; Alexander H. Maass; Michiel Rienstra; B. Daan Westenbrink

doi:10.1002/ejhf.43

Heart failure highlights in 2012-2013

Licette C. Y. Liu, Kevin Damman, Eric Lipsic, Alexander H. Maass, Michiel Rienstra, B. Daan Westenbrink^*

^*Bijbehorende auteur voor dit werk

Cardiovasculair Centrum

Onderzoeksoutput › peer review

8 Citaten (Scopus)

Samenvatting

Heart failure has become the cardiovascular epidemic of the century. The European Journal of Heart Failure is dedicated to the advancement of knowledge in the field of heart failure management. In 2012 and 2013, several pioneering scientific discoveries and paradigm-shifting clinical trials have been published. In the current paper, we will discuss the most significant novel insights into the pathophysiology, diagnosis, and treatment of heart failure that were published during this period. All relevant research areas are discussed, including pathophysiology, co-morbidities, arrhythmias, biomarkers, clinical trials, and device therapy, including left ventricular assist devices.

Originele taal-2	English
Pagina's (van-tot)	122-132
Aantal pagina's	11
Tijdschrift	European Journal of Heart Failure
Volume	16
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.1002/ejhf.43
Status	Published - feb.-2014

Toegang tot document

10.1002/ejhf.43

Handle.net

Permanente koppeling

Citeer dit

@article{d70ad93b55e940ca8b68637fbfa6452d,

title = "Heart failure highlights in 2012-2013",

abstract = "Heart failure has become the cardiovascular epidemic of the century. The European Journal of Heart Failure is dedicated to the advancement of knowledge in the field of heart failure management. In 2012 and 2013, several pioneering scientific discoveries and paradigm-shifting clinical trials have been published. In the current paper, we will discuss the most significant novel insights into the pathophysiology, diagnosis, and treatment of heart failure that were published during this period. All relevant research areas are discussed, including pathophysiology, co-morbidities, arrhythmias, biomarkers, clinical trials, and device therapy, including left ventricular assist devices.",

keywords = "Heart failure, Highlights 2012/13, Pathophysiology, Co-morbidities, Atrial fibrillation, Biomarkers, Pharmacological therapy, Interventional treatment, CRT, Assist devices, CARDIAC-RESYNCHRONIZATION THERAPY, PRESERVED EJECTION FRACTION, IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR, LEFT-VENTRICULAR DYSFUNCTION, MINERALOCORTICOID RECEPTOR ANTAGONIST, MECHANICAL CIRCULATORY SUPPORT, RANDOMIZED CONTROLLED-TRIAL, DIRECT RENIN INHIBITION, CHRONIC KIDNEY-DISEASE, ASSIST DEVICE SUPPORT",

author = "Liu, {Licette C. Y.} and Kevin Damman and Eric Lipsic and Maass, {Alexander H.} and Michiel Rienstra and Westenbrink, {B. Daan}",

note = "{\textcopyright} 2013 The Authors. European Journal of Heart Failure {\textcopyright} 2013 European Society of Cardiology.",

year = "2014",

month = feb,

doi = "10.1002/ejhf.43",

language = "English",

volume = "16",

pages = "122--132",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley",

number = "2",

}

TY - JOUR

T1 - Heart failure highlights in 2012-2013

AU - Liu, Licette C. Y.

AU - Damman, Kevin

AU - Lipsic, Eric

AU - Maass, Alexander H.

AU - Rienstra, Michiel

AU - Westenbrink, B. Daan

PY - 2014/2

Y1 - 2014/2

N2 - Heart failure has become the cardiovascular epidemic of the century. The European Journal of Heart Failure is dedicated to the advancement of knowledge in the field of heart failure management. In 2012 and 2013, several pioneering scientific discoveries and paradigm-shifting clinical trials have been published. In the current paper, we will discuss the most significant novel insights into the pathophysiology, diagnosis, and treatment of heart failure that were published during this period. All relevant research areas are discussed, including pathophysiology, co-morbidities, arrhythmias, biomarkers, clinical trials, and device therapy, including left ventricular assist devices.

AB - Heart failure has become the cardiovascular epidemic of the century. The European Journal of Heart Failure is dedicated to the advancement of knowledge in the field of heart failure management. In 2012 and 2013, several pioneering scientific discoveries and paradigm-shifting clinical trials have been published. In the current paper, we will discuss the most significant novel insights into the pathophysiology, diagnosis, and treatment of heart failure that were published during this period. All relevant research areas are discussed, including pathophysiology, co-morbidities, arrhythmias, biomarkers, clinical trials, and device therapy, including left ventricular assist devices.

KW - Heart failure

KW - Highlights 2012/13

KW - Pathophysiology

KW - Co-morbidities

KW - Atrial fibrillation

KW - Biomarkers

KW - Pharmacological therapy

KW - Interventional treatment

KW - CRT

KW - Assist devices

KW - CARDIAC-RESYNCHRONIZATION THERAPY

KW - PRESERVED EJECTION FRACTION

KW - IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR

KW - LEFT-VENTRICULAR DYSFUNCTION

KW - MINERALOCORTICOID RECEPTOR ANTAGONIST

KW - MECHANICAL CIRCULATORY SUPPORT

KW - RANDOMIZED CONTROLLED-TRIAL

KW - DIRECT RENIN INHIBITION

KW - CHRONIC KIDNEY-DISEASE

KW - ASSIST DEVICE SUPPORT

U2 - 10.1002/ejhf.43

DO - 10.1002/ejhf.43

M3 - Review article

C2 - 24464645

SN - 1388-9842

VL - 16

SP - 122

EP - 132

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 2

ER -